About the project
Abbott Laboratories is an American multinational medical devices and health care company, spanning pharmaceuticals, medical devices, diagnostic assays and nutritional products. With over 100,000 employees, global turnover is in excess of $40bn, with their glucose management FreeStyle product line representing 9% of total revenue.The growth in Diabetes Care revenue in 2020 and 2021 was mostly driven by the continued growth of FreeStyle Libre, Abbott’s continuous glucose monitoring system, internationally and in the U.S. In 2021, FreeStyle Libre sales reached $3.7 billion, which reflected a 36.8 percent increase compared to 2020, excluding the effect of foreign exchange. In 2020 its sales were $2.6 billion, which reflected a 42.6 percent increase, excluding the effect of foreign exchange, compared to 2019 when the sales totalled $1.8 billion.
Abbott’s third-quarter 2022 report shows worldwide sales of $10.4 billion in the corresponding period, raise of its full-year 2022 EPS guidance, and a strengthening of its position on the market with a new-gen FreeStyle Libre 3 system automatically delivering up-to-minute glucose readings via the smallest and tiniest in the world wearable sensor